CDT Moves AZD5904 into PCT Phase After 181-Subject Phase 1 Safety Data
CDT has advanced AZD5904, a potent human Myeloperoxidase inhibitor, into the Patent Cooperation Treaty phase to secure broader international IP protection. The asset has 181 subjects dosed across five Phase 1 studies with no drug-related adverse events and now holds composition of matter and method of use patents, with out-licensing discussions underway for idiopathic male and oncology-associated infertility.
1. AZD5904 Advances to PCT Phase
CDT has progressed AZD5904 into the Patent Cooperation Treaty stage, enabling the company to file for global patent protection beyond its existing U.S. and U.K. filings. This move paves the way for broader international coverage and strengthens the asset’s IP position ahead of later-stage development discussions.
2. Clinical Safety Data and Patent Portfolio
The inhibitor has been administered to 181 healthy volunteers across five Phase 1 studies, demonstrating a favorable safety profile with no overtly drug-related adverse events. CDT holds both a composition of matter patent and a method of use patent for AZD5904 in idiopathic male infertility, supported by preclinical efficacy data.
3. Partnering and Commercial Opportunity
With human validation and robust IP in place, CDT is engaging potential pharmaceutical partners for out-licensing and structured licensing arrangements. The company is targeting idiopathic male infertility and oncology-associated infertility indications, citing significant unmet need and commercial potential in these markets.